ARTICLE | Finance
First projects revealed under Flagship/GSK partnership: Venture Report
Plus: Nine-figure rounds for Solve, Artios and Aspen; and more
November 20, 2025 8:56 PM UTC
In the first agreements under a framework announced in July 2024, GSK is working with two Flagship portfolio companies to identify targets for respiratory and liver diseases.
GSK plc (LSE:GSK; NYSE:GSK) will work with ProFound Therapeutics Inc. to identify proteins associated with chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), using the biotech’s ProFoundry platform to interrogate the expanded human proteome...